Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Fentanyl;   Drug: Morphine;   Drug: Ticagrelor;   Drug: Aspirin;   Drug: Unfractioned Heparin;   Procedure: Primary PCI
Sponsors:   Centre Hospitalier Universitaire Vaudois;   AstraZeneca
Not yet recruiting - verified August 2015

Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)

Condition:   Intracranial Atherosclerosis
Interventions:   Device: Doctormate® (200mmHg);   Device: Doctormate® (60mmHg)
Sponsor:   Ji Xunming
Not yet recruiting - verified August 2015

Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP

Conditions:   Obstructive Sleep Apnea;   Acute Coronary Syndrome
Intervention:   Device: CPAP treatment
Sponsor:   Centre Hospitalier Universitaire de Saint Etienne
Recruiting - verified August 2015

Effect of Simvastatin Withdrawal on Ocular Endothelial Function

Condition:   Healthy
Interventions:   Device: Dynamic Vessel Analyzer (DVA);   Device: Laser Doppler Velocimetry (LDV);   Drug: Simvastatin
Sponsor:   Medical University of Vienna
Not yet recruiting - verified August 2015

Platelets Study: Influence of the Antiretroviral Treatment on the Platelet Physiology During HIV Infection

Condition:   Human Immunodeficiency Virus
Intervention:   Other: Blood samples
Sponsor:   Centre Hospitalier Universitaire de Saint Etienne
Completed - verified August 2015

GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels

Condition:   Thoracoabdominal Aortic Aneurysm
Intervention:   Device: GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis
Sponsor:   W.L.Gore & Associates
Not yet recruiting - verified August 2015

Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina

Condition:   Cardiovascular Diseases
Interventions:   Dietary Supplement: Beetroot Juice;   Dietary Supplement: Beetroot Juice
Sponsors:   Queen Mary University of London;   Imperial College London
Not yet recruiting - verified August 2015

Fructose and Ethnic Differences Study (FED Study)

Condition:   Healthy
Intervention:   Dietary Supplement: Dietary sugar
Sponsor:   King's College London
Completed - verified August 2015

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified August 2015

A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction

Condition:   Heart Failure
Interventions:   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: BAY1142524;   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified August 2015

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Condition:   Asthma
Interventions:   Drug: Interferon beta-1a Nebuliser solution 48 μg/mL;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography

Conditions:   Coronary Atherosclerosis;   Coronary Artery Disease;   Radiocontrast-induced Thyroid Dysfunction;   Contrast-induced Nephropathy
Interventions:   Radiation: Coronary computed tomography angiography;   Radiation: Quantitative coronary angiography
Sponsors:   Ural Medical University ;   Ural Institute of Cardiology;   De Haar Research Foundation
Enrolling by invitation - verified August 2015

Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis

Condition:   Aortic Stenosis
Intervention:   Procedure: surgical aortic valve replacement
Sponsor:   Clinical Centre of Serbia
Recruiting - verified August 2015

Study Apixaban to Vitamin K Antagonist for the Prevention of Stroke or Systemic Embolism and Bleeding in Patients With Non-valvular Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke Clinical Research Institute
Recruiting - verified August 2015

Identification of the Blood Microbiota in Patient Suffering From Myocardial Infraction

Conditions:   Coronary Disease;   Myocardial Infarction
Intervention:  
Sponsor:   University Hospital, Toulouse
Recruiting - verified August 2015

Benefits of Exercise Training in Women With Ischemic Syndrome

Condition:   Microvascular Coronary Dysfunction
Intervention:   Behavioral: Exercise training
Sponsor:   Cedars-Sinai Medical Center
Not yet recruiting - verified August 2015

Eplerenone in Heart Failure Treatment

Conditions:   Heart Failure;   Acute Myocardial Infarction;   Hypertension
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Recruiting - verified August 2015

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified August 2015

Role of PPAR-y Anonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)

Condition:   Systemic Lupus Erthematosus
Interventions:   Radiation: PET/CT;   Drug: Pioglitazone;   Procedure: Vascular function studies
Sponsor:   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified December 2014

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Acetylsalicylic acid;   Drug: Rivaroxaban;   Drug: Clopidogrel;   Drug: Ticagrelor
Sponsors:   Janssen Research & Development, LLC;   Bayer;   Duke Clinical Research Institute;   Harvard Medical School
Recruiting - verified August 2015

RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction

Conditions:   Heart Attack;   NSTEMI
Interventions:   Biological: AMI MultiStem cells;   Other: Sham
Sponsors:   Athersys, Inc;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2015

Left Bundle Branch Block ECG Characteristics in the Evaluation of Acute Coronary Syndrome

Condition:   Left Bundle Branch Block
Intervention:   Other: None - no intervention, observational study
Sponsor:   Duke University
Terminated - verified August 2015

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment

Conditions:   Cardiovascular Disease;   Atherosclerosis
Interventions:   Other: MRI;   Other: PET/MRI;   Other: Laboratory blood test
Sponsor:   Cedars-Sinai Medical Center
Recruiting - verified August 2015

PLATINUM Diversity

Conditions:   Atherosclerosis;   Coronary Artery Disease
Intervention:   Device: Percutaneous coronary intervention (Promus PREMIER)
Sponsor:   Boston Scientific Corporation
Active, not recruiting - verified August 2015

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR

Condition:   Peripheral Artery Disease (PAD)
Interventions:   Drug: Ticagrelor;   Drug: Comparator
Sponsors:   AstraZeneca;   CPC Clinical Research
Recruiting - verified August 2015

Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.

Condition:   Acute Coronary Syndrome
Interventions:   Drug: MEOPA and paracetamol;   Drug: Morphine
Sponsor:   University Hospital, Toulouse
Recruiting - verified August 2015

Telehealth Self-Management Program in Older Adults Living With Heart Failure in Health Disparity Communities

Condition:   Chronic Heart Failure
Interventions:   Device: Telehealth Self Management (TSM);   Other: Standard of Care
Sponsor:   North Shore Long Island Jewish Health System
Recruiting - verified August 2015

Canadian SCAD Study

Condition:   Spontaneous Coronary Artery Dissection
Intervention:  
Sponsors:   Cardiology Research UBC;   Canadian Institutes of Health Research  (CIHR)
Recruiting - verified August 2015

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: Dabigatran Etexilate 110mg;   Drug: Warfarin 3mg;   Drug: Aspirin;   Drug: Dabigatran Etexilate 150mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 5mg;   Drug: Clopidogrel or Ticagrelor;   Drug: Warfarin 1mg
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.

Condition:   Acute Myocardial Infarction
Interventions:   Biological: CSL112;   Biological: Placebo
Sponsor:   CSL Behring
Recruiting - verified August 2015

Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Treatment 90 days DAPT;   Drug: Treatment 360 days DAPT
Sponsor:   Diagram B.V.
Recruiting - verified August 2015

Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events

Condition:   Pulmonary Disease, Chronic Obstructive
Intervention:  
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified August 2015

Sequential Expansion of Comparative Effectiveness of Anticoagulants

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Aggressive hydraTion in Patients With ST -Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to prevenT Contrast-Induced Nephropathy

Condition:   ST Elevation Myocardial Infarction
Interventions:   Drug: Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride);   Drug: 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)
Sponsors:   Guangdong General Hospital;   Peking University First Hospital;   Chinese PLA General Hospital;   Fudan University
Recruiting - verified August 2015

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Conditions:   Pulmonary Embolism;   Thromboembolism;   Thrombosis;   Venous Thrombosis;   Venous Thromboembolism
Interventions:   Drug: BAY 59-7939;   Drug: BAY 59-7939;   Drug: ASA
Sponsor:   Bayer
Recruiting - verified August 2015

Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Troponin
Intervention:  
Sponsors:   Minneapolis Medical Research Foundation;   Abbott Diagnostics Division;   Hennepin County Medical Center, Minneapolis
Active, not recruiting - verified August 2015

Understanding the Exercise-Hypertension Paradox

Condition:   Hypertension
Interventions:   Dietary Supplement: Oral Antioxidant;   Other: Exercise rehabilitation
Sponsor:   Department of Veterans Affairs
Recruiting - verified August 2015

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified August 2015

Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.

Condition:   Platelet Reactivity
Interventions:   Drug: Clopidogrel and Ticagrelor;   Drug: Ticagrelor
Sponsor:   University of Patras
Completed - verified August 2015

Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis

Conditions:   ST Elevation Myocardial Infarction;   Fibrinolysis;   P2Y12 Inhibitor
Interventions:   Drug: Ticagrelor 180mg loading dose and 90mg bid maintenance dose;   Drug: Clopidogrel 600mg loading dose and 150mg maintenance dose
Sponsor:   University of Patras
Completed - verified August 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Germany)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Phenprocoumon
Sponsor:   Bayer
Recruiting - verified August 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxaban (Xarelto, Bay59-7939);   Drug: Warfarin
Sponsor:   Bayer
Recruiting - verified August 2015

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)

Condition:   Pulmonary Embolism
Interventions:   Drug: Rivaroxoban (Xarelto, Bay59-7939);   Drug: Acenocoumarol
Sponsor:   Bayer
Recruiting - verified August 2015

GLORIA-AF Registry Program (Phase II/III)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

Intensive Prevention Program After Myocardial Infarction

Conditions:   Myocardial Infarction.;   Prevention Harmful Effects.
Interventions:   Behavioral: Intensive Prevention Program;   Other: Standard medical and interventional therapy
Sponsors:   Herzzentrum Bremen;   Oldenburger Forschungs- und Entwicklungsinstitut für Informatik (OFFIS).
Recruiting - verified August 2015

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified August 2015

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified August 2015

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified August 2015

A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Conditions:   Atrial Fibrillation;   Percutaneous Coronary Intervention
Interventions:   Drug: rivaroxaban 2.5 mg;   Drug: rivaroxaban 15 mg;   Drug: rivaroxaban 10 mg;   Drug: aspirin (ASA);   Drug: vitamin K antagonist (VKA);   Drug: clopidogrel;   Drug: prasugrel;   Drug: ticagrelor
Sponsors:   Janssen Scientific Affairs, LLC;   Bayer
Active, not recruiting - verified August 2015

Surgical Pulmonary Vein Isolation Efficiency Study

Conditions:   Paroxysmal Atrial Fibrillation;   Coronary Artery Disease
Interventions:   Procedure: CABG, AVR or CABG+AVR and PVI;   Procedure: CABG, AVR or CABG+AVR
Sponsor:   Kuopio University Hospital
Terminated - verified August 2015

The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention

Condition:   Acute Coronary Syndrome
Intervention:  
Sponsors:   University of Patras;   Hellenic Cardiological Society
Completed - verified August 2015

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Active, not recruiting - verified August 2015

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

A Randomized Clinical Evaluation of the BioFreedom™ Stent

Conditions:   Stable Angina;   Ischemic Heart Disease Silent;   ST Elevation (STEMI) and Non-ST Elevation (NSTEMI) Myocardial Infarction;   In-stent Coronary Artery Restenosis;   Bleeding
Interventions:   Device: Biofreedom™ Drug Coated Stent (DCS);   Device: Gazelle™ Bare Metal Coronary Stent (BMS)
Sponsors:   Biosensors Europe SA;   European Cardiovascular Research  Center
Active, not recruiting - verified August 2015

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified August 2015

Safety and Effectiveness of Intra-coronary Nitrite in Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   Reperfusion Injury;   Myocardial Ischemia;   Cardiovascular Diseases
Interventions:   Drug: Sodium Nitrite;   Drug: Sodium Chloride Placebo
Sponsors:   Barts & The London NHS Trust;   Queen Mary University of London
Active, not recruiting - verified July 2015

Left Atrial Appendage Occlusion Study III

Conditions:   Cardiac Surgery With Cardiopulmonary Bypass;   Atrial Fibrillation
Intervention:   Other: Left Atrial Appendage Occlusion
Sponsor:   Population Health Research Institute
Recruiting - verified August 2015

Controlled Level EVERolimus in Acute Coronary Syndromes

Condition:   Acute Coronary Syndromes
Interventions:   Drug: Everolimus;   Drug: Placebo
Sponsors:   University of Zurich;   Swiss National Science Foundation;   Novartis
Recruiting - verified August 2015

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified August 2015

METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease

Condition:   Chronic Ischemic Heart Disease
Interventions:   Other: intramyocardial injection of BM cells;   Other: intramyocardial / intracoronary injection of BM cells;   Other: Best medical therapy
Sponsor:   Cardiocentro Ticino
Terminated - verified August 2015

Stress Echocardiography and Heart Computed Tomography (CT) Scan in Emergency Department Patients With Chest Pain

Conditions:   Chest Pain;   Angina;   Angina Pectoris;   Coronary Artery Disease
Interventions:   Procedure: Stress Echocardiography;   Procedure: Coronary CT Angiography
Sponsors:   Montefiore Medical Center;   American Heart Association
Recruiting - verified August 2015

A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention

Condition:   Myocardial Infarction
Interventions:   Procedure: Percutaneous Coronary Intervention (PCI);   Drug: RO4905417;   Drug: RO4905417;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

A Study of RoActemra/Actemra (Tocilizumab) in Comparison to Etanercept in Patients With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

Condition:   Cardiovascular Disease, Rheumatoid Arthritis
Interventions:   Drug: etanercept;   Drug: tocilizumab [RoActemra/Actemra]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified August 2015

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

Condition:   Severe Aortic Stenosis
Interventions:   Device: Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI);   Device: Surgical Aortic Valve Replacement (SAVR)
Sponsor:   Medtronic Cardiovascular
Active, not recruiting - verified August 2015

The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction

Conditions:   Acute Myocardial Infarction;   Ischemia-reperfusion Injury
Interventions:   Drug: Melatonin, N-acetyl-5-methoxytryptamine;   Drug: Isotonic saline, Natrium chloride
Sponsor:   Herlev Hospital
Recruiting - verified August 2015

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified August 2015

CANVAS - CANagliflozin cardioVascular Assessment Study

Conditions:   Diabetes Mellitus, Type 2;   Cardiovascular Diseases;   Risk Factors
Interventions:   Drug: Canagliflozin (JNJ-28431754);   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Active, not recruiting - verified August 2015

A Study of All-Cause Mortality and Cardiovascular Morbidity in CKD Patients on Dialysis and Those Not on Renal Replacement Therapy Receiving Mircera or Reference ESAs.

Condition:   Anemia
Interventions:   Drug: ESAs (darbepoetin alfa, epoetin alfa or epoetin beta);   Drug: methoxy polyethylene glycol-epoetin beta [Mircera];   Drug: methoxy polyethylene glycol-epoetin beta [Mircera]
Sponsor:   Hoffmann-La Roche
Active, not recruiting - verified August 2015

Study Comparing CT Scan and Stress Test in Diagnosing Coronary Artery Disease in Patients Hospitalized for Chest Pain

Conditions:   Coronary Artery Disease;   Angina Pectoris;   Unstable Angina;   Acute Coronary Syndrome
Interventions:   Procedure: Coronary Computed Tomography Angiography;   Procedure: Stress Nuclear Myocardial Perfusion Imaging
Sponsors:   Montefiore Medical Center;   American Heart Association;   Albert Einstein College of Medicine of Yeshiva University
Completed - verified August 2015

Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents.Intervention Trial

Conditions:   Type 2 Diabetes Mellitus;   Cardiovascular Disease
Interventions:   Drug: add-on pioglitazone;   Drug: add-on sulphonylurea
Sponsors:   Italian Society of Diabetology;   Associazione Medici Diabetologi (AMD);   Associazione Nazionale Medici Cardiologi Ospedalieri
Active, not recruiting - verified August 2015

Left Ventricular Function Assessment After Acute Myocardial Infarction: Comparison Between Bi-, Three-dimensional and Cardiac Magnetic Resonance

Condition:   Acute Myocardial Infarction
Intervention:   Other: compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)
Sponsor:   Assistance Publique Hopitaux De Marseille
Completed - verified June 2008

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Active, not recruiting - verified August 2015

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

Conditions:   Lymphoma;   Leukemia;   Myeloproliferative Disorders;   Multiple Myleoma;   Myelodysplastic Syndrome
Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclosporine;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Biological: T-Rapa cell DLI;   Procedure: T cell DLI;   Drug: Prednisone;   Procedure: Allogeneic HSCT;   Drug: Filgrastim
Sponsor:   National Cancer Institute (NCI)
Suspended - verified September 2014

Effects of Disease Management on Development of End Stage Renal Disease in Type 2 Diabetic Patients With Nephropathy

Conditions:   Type 2 Diabetes Mellitus;   DM Nephropathy
Intervention:   Behavioral: Multidisciplinary team care
Sponsor:   Chinese University of Hong Kong
Completed - verified August 2015

SDCC - Prospective Cohort Study of Chronic Renal Insufficiency

Condition:   Renal Insufficiency, Chronic
Intervention:  
Sponsors:   University of Pennsylvania;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Johns Hopkins University;   Case Western Reserve University;   University of Michigan;   University of Illinois at Chicago;   Tulane University;   Kaiser Permanente
Active, not recruiting - verified August 2015

Insulin Resistance Intervention After Stroke Trial

Conditions:   Stroke;   Myocardial Infarction;   Diabetes
Interventions:   Drug: pioglitazone;   Drug: placebo
Sponsors:   Yale University;   National Institute of Neurological Disorders and Stroke (NINDS);   Takeda Pharmaceuticals North America, Inc.
Active, not recruiting - verified August 2015

Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia

Conditions:   Graft vs Host Disease;   Hematologic Neoplasm;   Leukemia;   Multiple Myeloma;   Myelodysplastic Syndrome
Intervention:   Procedure: Allogeneic Bone Marrow Transplant
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified August 2015

Get CardioSmart

You're Invited